Tag: anti-PD-1

1. Overall survival and progression-free survival were higher for patients on nivolumab plus chemotherapy compared to chemotherapy alone. 2. Severe adverse events occurred more frequently in the nivolumab group and more patients withdrew from treatment due to these events. Evidence Rating Level: 1 (Excellent) Study Rundown: The 5-year survival rate of patients...
Click to read the study in the European Journal of Cancer. 
Click to read the study in The Lancet Oncology. Click to see previously reported survival outcomes from the same cohort.